Source:http://linkedlifedata.com/resource/pubmed/id/10960722
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2000-10-25
|
pubmed:abstractText |
Elevated proinsulin secretion and islet amyloid deposition are both features of Type 2 diabetes but their relationship to beta-cell dysfunction is unknown. To determine if islet amyloid polypeptide (IAPP) secretion is disproportionate with other beta-cell products at any stage of glucose intolerance, 116 subjects were studied. Non-diabetic subjects with equivalent body mass index (BMI) were assigned to three groups, (i) normal fasting glucose, fpg<5.5 mmol l(-1); (ii) intermediate fasting glucose, fpg> or =5.5<6.15 mmol l(-1); (iii) impaired fasting glucose (IFG), fpg> or =6.1<7.0 mmol l(-1). Diabetic subjects were divided according to therapy (9 diet, 19 tablet, and 11 insulin). IAPP, C-peptide and proinsulin were measured fasting and at the end of a 1-h glucose infusion. Fasting C-peptide, IAPP and proinsulin were significantly elevated in the IFG group compared with the other non-diabetic groups (P<0.02); fasting IAPP/C-peptide and proinsulin/C-peptide were 1-2% in all non-diabetic groups. Fasting and 1-h proinsulin and proinsulin/C-peptide were higher in diabetic compared with non-diabetic subjects (P<0.01). IAPP and IAPP/C-peptide in diabetic groups were similar to that in non-diabetic subjects but reduced in the insulin-treated group (P<0.01). Proinsulin was disproportionately increased compared with C-peptide and IAPP in Type 2 diabetes particularly in severe beta-cell failure implying more than one concurrent beta-cell pathology.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Amyloid,
http://linkedlifedata.com/resource/pubmed/chemical/Blood Glucose,
http://linkedlifedata.com/resource/pubmed/chemical/C-Peptide,
http://linkedlifedata.com/resource/pubmed/chemical/Hypoglycemic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Insulin,
http://linkedlifedata.com/resource/pubmed/chemical/Islet Amyloid Polypeptide,
http://linkedlifedata.com/resource/pubmed/chemical/Proinsulin
|
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0168-8227
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
50
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
117-26
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:10960722-Amyloid,
pubmed-meshheading:10960722-Blood Glucose,
pubmed-meshheading:10960722-Body Mass Index,
pubmed-meshheading:10960722-C-Peptide,
pubmed-meshheading:10960722-Diabetes Mellitus, Type 1,
pubmed-meshheading:10960722-Diabetes Mellitus, Type 2,
pubmed-meshheading:10960722-Fasting,
pubmed-meshheading:10960722-Female,
pubmed-meshheading:10960722-Glucose Intolerance,
pubmed-meshheading:10960722-Glucose Tolerance Test,
pubmed-meshheading:10960722-Humans,
pubmed-meshheading:10960722-Hypoglycemic Agents,
pubmed-meshheading:10960722-Insulin,
pubmed-meshheading:10960722-Islet Amyloid Polypeptide,
pubmed-meshheading:10960722-Longitudinal Studies,
pubmed-meshheading:10960722-Male,
pubmed-meshheading:10960722-Middle Aged,
pubmed-meshheading:10960722-Proinsulin,
pubmed-meshheading:10960722-Reference Values
|
pubmed:year |
2000
|
pubmed:articleTitle |
Parallel changes of proinsulin and islet amyloid polypeptide in glucose intolerance.
|
pubmed:affiliation |
Diabetes Research Laboratories, Radcliffe Infirmary, Woodstock Road, OX2 6HE, Oxford, UK.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|